Mutations in the RAS and @entity10412 pathways are associated with metastatic location in XXXX .

@entity1 @entity470 @entity5 @entity584 @entity10412 @entity983 @entity14 @entity3 @entity8497 @entity8496
BACKGROUND AND OBJECTIVES: Identification of mutations in the downstream @entity470 ( @entity470 ) signaling pathway could provide important insights of @entity470 -targeted therapies in @entity14 . We analyzed the mutation spectra of the @entity10412 / @entity983 / @entity584 and RAS/ @entity8496 /MAPK pathways in @entity14 and the associations of these mutations with sites of @entity3 or recurrence. METHODS: The study population comprised 1,492 retrospectively collected stages I-IV @entity14 specimens. Tissue was obtained between 2000 and 2010 at a single hospital. We analyzed 61 hot spots using MALDI-TOF mass spectrometry for nucleic acid analysis. RESULTS: Mutations were found in the RAS pathway in 47.3% of @entity1 and in the @entity10412 pathway in 14.3% of @entity1 , with 9.2% of @entity1 carrying mutations in both pathways. Both the RAS and @entity10412 pathway mutations were significantly associated with proximal @entity5 , @entity5 , and microsatellite instability. @entity5 carrying a RAS pathway mutation exhibited a higher frequency of lung and peritoneal @entity3 than did @entity5 with a wild-type gene (P   =   0.025 and 0.009, respectively). @entity8497 gene mutation was significantly associated with lung @entity3 (P   =   0.001). CONCLUSIONS: Somatic mutations in the RAS pathway of the @entity5 in @entity14 can influence patterns of @entity3 and recurrence.
